Skip to main content
Clinical Trials/NL-OMON49946
NL-OMON49946
Not yet recruiting
Phase 3

A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-IC patients with COVID-19 infections - COV-PLAS

eids Universitair Medisch Centrum0 sites430 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
eids Universitair Medisch Centrum
Enrollment
430
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Maximal 3 days hospitalized patients at plasma infusion.
  • 2\. Age \* 18 years and \* 85 years
  • 3\. SARS\-CoV\-2 infection: confirmed by PCR (BAL, sputum, nasal and/or pharyngeal
  • 4\. Symptoms not expected to lead to IC transfer within 6 hours of first plasma
  • administration
  • 5\. Written informed consent including storing of specimen for future testing

Exclusion Criteria

  • 1\. Accompanying diseases other than COVID\-19 with an expected survival time of
  • less than 12 months
  • 2\. Chronic obstructive lung disease (COPD), stage 4
  • 3\. Lung fibrosis with UIP pattern in CT und Severe emphysema
  • 4\. Chronic heart failure NYHA \>\= 3 and/or pre\-existing reduction of left
  • ventricular ejection fraction to \* 30%
  • 5\. Cardiovascular failure requiring diuretics
  • 6\. Signs of severe coagulopathy : thrombocytopenia a/o prolongation of the
  • PT/INR, PTT a/o elevation of D\-dimer, a/o decreased fibrinogen level waardes ?
  • 7\. Liver cirrhosis Child C

Outcomes

Primary Outcomes

Not specified

Similar Trials